469 related articles for article (PubMed ID: 29020964)
1. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
2. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.
Fahmi A; Smart N; Punn A; Jabr R; Marber M; Heads R
Cell Signal; 2013 Apr; 25(4):898-909. PubMed ID: 23268184
[TBL] [Abstract][Full Text] [Related]
3. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.
Adachi Y; Aoki C; Yoshio-Hoshino N; Takayama K; Curiel DT; Nishimoto N
Int J Cancer; 2006 Sep; 119(6):1303-11. PubMed ID: 16642474
[TBL] [Abstract][Full Text] [Related]
5. "Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells.
Trilling M; Le VT; Rashidi-Alavijeh J; Katschinski B; Scheller J; Rose-John S; Androsiac GE; Jonjic S; Poli V; Pfeffer K; Hengel H
J Immunol; 2014 Jan; 192(1):447-58. PubMed ID: 24319264
[TBL] [Abstract][Full Text] [Related]
6. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
7. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
8. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of gingival inflammation induced by synergism of IL-1β and IL-6.
Sawada S; Chosa N; Ishisaki A; Naruishi K
Biomed Res; 2013 Feb; 34(1):31-40. PubMed ID: 23428978
[TBL] [Abstract][Full Text] [Related]
10. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
11. Soluble IL-6 Receptor and IL-27 Subunit p28 Protein Complex Mediate the Antiviral Response through the Type III IFN Pathway.
Yang X; Hao H; Xia Z; Xu G; Cao Z; Chen X; Liu S; Zhu Y
J Immunol; 2016 Sep; 197(6):2369-81. PubMed ID: 27527594
[TBL] [Abstract][Full Text] [Related]
12. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines.
Marley GM; Doyle LA; Ordóñez JV; Sisk A; Hussain A; Yen RW
Cancer Res; 1989 Nov; 49(22):6232-6. PubMed ID: 2553249
[TBL] [Abstract][Full Text] [Related]
14. Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.
Wilmes S; Jeffrey PA; Martinez-Fabregas J; Hafer M; Fyfe PK; Pohler E; Gaggero S; López-García M; Lythe G; Taylor C; Guerrier T; Launay D; Mitra S; Piehler J; Molina-París C; Moraga I
Elife; 2021 Apr; 10():. PubMed ID: 33871355
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
[TBL] [Abstract][Full Text] [Related]
17. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.
Regis G; Icardi L; Conti L; Chiarle R; Piva R; Giovarelli M; Poli V; Novelli F
Leukemia; 2009 Nov; 23(11):2102-8. PubMed ID: 19626047
[TBL] [Abstract][Full Text] [Related]
18. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts.
Vermes C; Jacobs JJ; Zhang J; Firneisz G; Roebuck KA; Glant TT
J Biol Chem; 2002 May; 277(19):16879-87. PubMed ID: 11884403
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.
Petretto A; Carbotti G; Inglese E; Lavarello C; Pistillo MP; Rigo V; Croce M; Longo L; Martini S; Vacca P; Ferrini S; Fabbi M
Oncotarget; 2016 Nov; 7(45):72518-72536. PubMed ID: 27683036
[TBL] [Abstract][Full Text] [Related]
20. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
